Brian Joseph Cahill Eagle Pharmaceuticals, Inc. (EGRX) insider trading activity

Brian Joseph Cahill is CHIEF FINANCIAL OFFICER of EAGLE PHARMACEUTICALS, INC.. Currently has a direct ownership of 47,958 shares of EGRX, which is worth approximately $23,979. The most recent transaction as insider was on Feb 27, 2024, when has been sold 1,589 shares (Common Stock) at a price of $6.44 per share, resulting in proceeds of $10,233. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 48K

0% 3M change

1.14% 12M change

Total Value Held $23,979

Brian Joseph Cahill Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 27 2024	SELL Payment of exercise price or tax liability	$10,233 $6.44 p/Share	1,589 Reduced 3.21%	47,958 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	3,800 Added 7.12%	49,547 Common Stock
Feb 02 2024	SELL Payment of exercise price or tax liability	$5,463 $5.85 p/Share	934 Reduced 2.0%	45,747 Common Stock
Jan 05 2024	SELL Payment of exercise price or tax liability	$3,770 $5.13 p/Share	735 Reduced 1.55%	46,681 Common Stock
Dec 18 2023	SELL Payment of exercise price or tax liability	$2,151 $4.76 p/Share	452 Reduced 0.94%	47,416 Common Stock
Mar 01 2023	BUY Grant, award, or other acquisition	-	18,500 Added 27.87%	47,868 Common Stock
Feb 28 2023	SELL Payment of exercise price or tax liability	$20,104 $28.0 p/Share	718 Reduced 2.39%	29,368 Common Stock
Feb 02 2023	SELL Payment of exercise price or tax liability	$26,760 $34.09 p/Share	785 Reduced 2.54%	30,086 Common Stock
Jan 30 2023	SELL Payment of exercise price or tax liability	$19,959 $33.21 p/Share	601 Reduced 1.91%	30,871 Common Stock
Jan 05 2023	SELL Payment of exercise price or tax liability	$21,476 $29.26 p/Share	734 Reduced 2.28%	31,472 Common Stock
Dec 19 2022	SELL Payment of exercise price or tax liability	$13,843 $30.03 p/Share	461 Reduced 1.41%	32,206 Common Stock
Feb 28 2022	BUY Grant, award, or other acquisition	-	8,000 Added 19.67%	32,667 Common Stock
Feb 02 2022	SELL Payment of exercise price or tax liability	$36,249 $45.03 p/Share	805 Reduced 3.16%	24,667 Common Stock
Jan 31 2022	SELL Payment of exercise price or tax liability	$28,758 $45.94 p/Share	626 Reduced 2.4%	25,472 Common Stock
Jan 07 2022	SELL Payment of exercise price or tax liability	$13,316 $50.63 p/Share	263 Reduced 1.0%	26,098 Common Stock
Jan 05 2022	SELL Payment of exercise price or tax liability	$37,409 $50.69 p/Share	738 Reduced 2.72%	26,361 Common Stock
Dec 20 2021	SELL Payment of exercise price or tax liability	$25,881 $55.42 p/Share	467 Reduced 1.69%	27,099 Common Stock
Feb 02 2021	BUY Grant, award, or other acquisition	-	8,900 Added 24.41%	27,566 Common Stock
Jan 29 2021	SELL Payment of exercise price or tax liability	$29,729 $46.67 p/Share	637 Reduced 3.3%	18,666 Common Stock
Jan 07 2021	SELL Payment of exercise price or tax liability	$12,080 $50.97 p/Share	237 Reduced 1.63%	14,303 Common Stock
Jan 05 2021	SELL Payment of exercise price or tax liability	$37,315 $50.02 p/Share	746 Reduced 4.88%	14,540 Common Stock
Dec 18 2020	BUY Grant, award, or other acquisition	-	5,000 Added 20.57%	19,303 Common Stock

BJC

Brian Joseph Cahill

CHIEF FINANCIAL OFFICER

Woodcliff Lake, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells EGRX shares.

Notify only if

Value

Insider Trading

Get notified when an Eagle Pharmaceuticals, Inc. insider buys or sells EGRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to EAGLE PHARMACEUTICALS, INC.

Track Activities on EGRX

Account